4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Essex Bio-Technology Limited (1061) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Zhuhai, China with about 1,240 employees. Its market capitalization is roughly HK$1 billion. In the fiscal year ended 2025-12-31, 1061 reported HK$1.8B in revenue and HK$318M in net income.
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments.
Interactive charts & full statements → Open the 1061 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | HK$1.8B | HK$1.7B | HK$1.7B | HK$1.3B | — |
| Gross Profit | HK$1.6B | HK$1.5B | HK$1.6B | HK$1.2B | — |
| Operating Income (EBIT) | HK$414M | HK$355M | HK$334M | HK$282M | — |
| Net Income | HK$318M | HK$307M | HK$275M | HK$225M | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (HK$74M) | (HK$60M) | (HK$40M) | (HK$54M) | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | HK$3.5B | HK$3.0B | HK$2.8B | HK$2.7B | — |
| Total Liabilities | HK$1.1B | HK$859M | HK$904M | HK$981M | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1061 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms